Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Colorectal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Carcinoma 2Adenocarcinoma 2Spinocerebellar Degenerations 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Colorectal Cancer Liver Metastases 1Colonic Neoplasms 1Advanced Colorectal Cancer 1

Interventions

Imatinib Mesylate 19Sunitinib 9nilotinib 4ripretinib 3regorafenib 2masitinib 2tanespimycin 1famitinib 1avapritinib 1Sodium Chloride 1Midazolam 1Mastectomy, Segmental 1Immunoglobulin G 1IDRX-42 1Fentanyl 1Disulfides 1Carnitine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × regorafenib × Clear all
NCT03465722 2022-10-06

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Phase 3 Completed
476 enrolled 14 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01271712 2021-01-29

GRID

Bayer

Phase 3 Completed
199 enrolled 17 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡